Organon公司宣布，其产品Tofidence®（托珠单抗-Bavi）已获得美国食品药品监督管理局的批准，新增两项重要适应症。此次获批将允许该药物用于治疗细胞因子释放综合征，以及儿童新型冠状病毒感染患者。这一决定有望为相关患者群体提供新的治疗选择，并拓展该药物的临床应用范围。
Organon公司宣布，其产品Tofidence®（托珠单抗-Bavi）已获得美国食品药品监督管理局的批准，新增两项重要适应症。此次获批将允许该药物用于治疗细胞因子释放综合征，以及儿童新型冠状病毒感染患者。这一决定有望为相关患者群体提供新的治疗选择，并拓展该药物的临床应用范围。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.